AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$TWST

WERNER ROBERT F. sold $213K of TWST

WERNER ROBERT F. (Chief Accounting Officer) sold 1,523 shares of Twist Bioscience Corp (TWST) at an average of $140.02 ($139.07–$140.77, $0.21M total) across 2 trades over 2026-08-21 to 2026-08-24.

Original reporting
SEC EDGAR · WERNER ROBERT F.
Published Aug 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming financing or compensation events not disclosed.

Relevance 4/10Novelty 4/10Timing: post-filing

Background

Form 4 filings disclose insider transactions; traders monitor for signals.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Chief Accounting Officer sold 1,523 shares for $213K, reducing his stake to 44,637 shares.

Expected impact

Potential slight downward pressure in short term.

Evidence & confidence

Sale amount is under $1M and represents a small percentage of total holdings; market reaction likely limited.

Market effects

Sector

Minimal impact on biotech sector; insider activity is routine.

Regional

No regional effect.

Global

Limited to Twist Bioscience investors.

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; insider may need liquidity.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech company listed on NASDAQ.

  • Insider
    Werner Robert F.

    Chief Accounting Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 8
$TWSTMed

Jefferies initiates Twist Bioscience stock at Hold on valuation

Jefferies initiated coverage on Twist Bioscience (TWST) with a Hold rating and $150 price target, citing premium valuation. The stock trades at $155.65 after a 391% YTD surge. Jefferies notes its market differentiation and AI-driven growth, but warns of high valuation expectations. TWST partners with Eli Lilly's TuneLab for AI/ML drug discovery, while BWS Financial rates it Sell, and Guggenheim reiterates Buy.

investing.com2 min
OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min